← Eichor
Study identifier: NCT07662655 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Hypertension After Transcatheter Mitral Valve Edge-to-Edge Repair (M-TEER): A Prospective Cohort Study

Condition: Pulmonary Hypertension · Pulmonary Hypertension Associated With HFpEF  ·  Sponsor: Xiamen Cardiovascular Hospital, Xiamen University

PhaseEARLY_Phase 1
Planned participants60
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

this study aims to investigate the efficacy and safety of PADN therapy compared with standard medical therapy in patients diagnosed with pulmonary hypertension after M-TEER, thereby providing evidence for clinical treatment decision-making

This description comes directly from the study's public registry record.

Talk to the study team

Xiang CHEN, Dr  ·  +8618033997788  ·  seanchenx@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Structural Heart Disease Unit, Xiamen Cardiovacular HospitalXiamen, Fujian, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07662655